00000000cam 2200000zi 4500
0019.966906
003CaOODSP
00520261113134352
006m     o  d f      
007cr cn|||||||||
008261019e202611  onca    ob   f000 0 eng d
020 |a9781100010342
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-327/2026E-1-PDF
24500|aGuidance on nitrosamine impurities in medications : |bevaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products.
250 |a[November 2026 edition].
264 1|a[Ottawa] : |bHealth Canada = Santé Canada, |cNovember 2026.
264 4|c©2026
300 |a1 online resource (iii, 64 pages) : |billustrations
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aTitle from cover.
500 |aIssued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments : évaluation et gestion des risques posés par les impuretés de N-nitrosamine dans les produits pharmaceutiques, biologiques et radiopharmaceutiques destinés à l'usage humain.
500 |a"Health products."
504 |aIncludes bibliographical references (page 37).
520 |a"This guidance represents Health Canada's current thinking and recommendations on issues related to N-nitrosamine impurities (nitrosamine impurities or nitrosamines). This guidance may be subject to change as new information becomes available and if further guidance is needed for applicants and market authorization holders (MAHs)"--Background, page 1.
650 0|aNitrosoamines|xRisk assessment|zCanada.
650 0|aDrugs|xRisk assessment|zCanada.
650 0|aBiologicals|xRisk assessment|zCanada.
650 0|aRadiopharmaceuticals|xRisk assessment|zCanada.
650 0|aPharmaceutical policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLignes directrices sur les impuretés de nitrosamine dans les médicaments : |w(CaOODSP)9.966905
795 |tGuidance on nitrosamine impurities in medications.|w(CaOODSP)9.962669
85640|qPDF|s2.02 MB|uhttps://publications.gc.ca/collections/collection_2026/sc-hc/H164-327-2026-1-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html